Eniola Olutogun’s research aligns well with Horizon Europe’s focus on **neuropharmacology, computational neuroscience, and AI-driven drug discovery**, particularly under clusters like **Health (HORIZON-CL4-2024)** or **Digital, Industry and Space (DIGITAL)**. Their **CCT model, neurocascade simulations, and TOPOLOGIX drug-resistance work** directly target addiction neuroscience and precision medicine—key themes in EU health R&D. The **LMIC/Africa angle** could also fit calls addressing global health disparities (e.g., **HORIZON-INFRA-2024-DEV** or **HORIZON-MISS-2024**). Their **independent researcher status** and **collaborations with EU-based PIs (e.g., Berridge, Gershman)** strengthen eligibility for early-career grants.